Response Prediction of ^{177}Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

Hendrik Rathke[1], Tim Holland-Letz[2], Walter Mier[1], Paul Flechsig[1], Eleni Mavriopoulou[1], Manuel Röhrich[1], Klaus Kopka[3], Markus Hohenfellner[4], Frederik Lars Giesel[1], Uwe Haberkorn[1,4–6], and Clemens Kratochwil[1]

[1]Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; [2]Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany; [3]Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany; [4]Department of Urology, University Hospital Heidelberg, Heidelberg, Germany; [5]Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and [6]Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany

Neuroendocrinelike transdifferentiation of prostate cancer adenocarcinomas correlates with serum levels of chromogranin A (CgA) and drives treatment resistance. The aim of this work was to evaluate whether CgA can serve as a response predictor for ^{177}Lu-prostate-specific membrane antigen 617 (PSMA) radioligand therapy (RLT) in comparison with the established tumor markers. **Methods:** One hundred consecutive patients with metastasized castration-resistant prostate cancer scheduled for PSMA RLT were evaluated for prostate-specific antigen (PSA), lactate dehydrogenase (LDH), and CgA at baseline and in follow-up of PSMA RLT. Tumor uptake of PSMA ligand, a known predictive marker for response, was assessed as a control variable. **Results:** From the 100 evaluated patients, 35 had partial remission, 16 stable disease, 15 mixed response, and 36 progression of disease. Tumor uptake above salivary gland uptake translated into partial remission, with an odds ratio (OR) of 60.265 (95% confidence interval [CI], 5.038–720.922). Elevated LDH implied a reduced chance for partial remission, with an OR of 0.094 (95% CI, 0.017–0.518), but increased the frequency of progressive disease (OR, 2.717; 95% CI, 1.391–5.304). All patients who achieved partial remission had a normal baseline LDH. Factor-2 elevation of CgA increased the risk for progression, with an OR of 3.089 (95% CI, 1.302–7.332). Baseline PSA had no prognostic value for response prediction. **Conclusion:** In our cohort, baseline PSA had no prognostic value for response prediction. LDH was the marker with the strongest prognostic value, and elevated LDH increased the risk for progression of disease under PSMA RLT. Elevated CgA demonstrated a moderate impact as a negative prognostic marker in general but was explicitly related to the presence of liver metastases. Well in line with the literature, sufficient tumor uptake is a prerequisite to achieve tumor response.

Key Words: prostate cancer; PSMA; radioligand therapy; neuroendocrine differentiation; response prediction

Androgen deprivation therapy followed by novel androgen-axis drugs such as enzalutamide and abiraterone have been shown to improve overall survival in patients with prostate cancer (1,2). For patients with metastasized castration-resistant prostate cancer who have exhausted standard therapies, prostate-specific membrane antigen therapy became a possible last-line therapy (3).

De novo neuroendocrine prostate cancer is uncommon (~1%); however, after multiple treatment lines, up to 40% of patients initially diagnosed with adenocarcinoma present a conversion or transdifferentiation of prostate adenocarcinoma into neuroendocrinelike cells, also named treatment-related neuroendocrine prostate cancer (4,5). During this tumor evolution to high-grade prostate cancer, pluripotent tumor stem cells undergo epithelial–mesenchymal transition, and the increasing number of neuroendocrine cells, which are not regulated by androgens, contributes to acquired resistance against antihormonal therapies (6–8). The increase of neuroendocrine cells between early- and advanced-stage prostate cancer may result in elevated serum chromogranin A (CgA) levels.

CgA is an acidic glycoprotein, commonly overexpressed by neuroendocrine cells and released to the blood by secretory granules (6). In patients with prostate cancer, CgA is released by primary tumors and also metastases and is considered a possible surrogate reflecting the increase in neuroendocrinelike cells in advanced-stage metastasized castration-resistant prostate cancer (9). Several studies described high CgA levels to be related to high-grade prostate cancer (10), advanced-stage disease with a poor prognosis, resistance against enzalutamide and abiraterone (6,7), and reduced overall survival (8,11). Neuron-specific enolase, also suggested as a potential neuroendocrine biomarker, was recently reported to have lower sensitivity and specificity than CgA (8,12).

Similarly to neuroendocrine transdifferentiation, prostate-specific membrane antigen overexpression was also reported to increase in advanced-stage, hormone-resistant tumors (13). Until now, no data about prostate-specific membrane antigen expression in treatment-related neuroendocrine prostate cancer have been available. However, for treatment-related neuroendocrine prostate cancer, resistance mechanisms to subsequent treatments (radiation therapy, androgen deprivation therapy, second-generation antihormonal

therapy, and chemotherapy) are known (5,7). This knowledge leads to the question of whether partial neuroendocrine transdifferentiation might also increase resistance against ^{177}Lu-prostate-specific membrane antigen 617 (PSMA) radioligand therapy (RLT).

The aim of this study was to evaluate whether CgA is a potential prognostic marker in metastasized castration-resistant prostate cancer patients treated with PSMA RLT and how this biomarker may perform in comparison to other established tumor markers such as prostate-specific antigen (PSA) and lactate dehydrogenase (LDH).

MATERIALS AND METHODS

Patients

Patients with metastasized castration-resistant prostate cancer after exhausting (or being considered ineligible for) approved treatment options were treated with PSMA RLT under the conditions of the updated Declaration of Helsinki, article 37, "Unproven Interventions in Clinical Practice." One hundred consecutive patients who had received PSMA were selected for this study. With awareness of receiving an experimental therapy, all patients gave written informed consent. The retrospective data evaluation was approved by our institutional review board.

Patient history and current drug medication plan were explored for known confounders of CgA serum levels; that is, patients with chronic atrophic gastritis (14), long-term use of proton-pump inhibitors (15), reduced renal function (16), and chronic heart failure (17). All 100 patients and a subgroup of 65 patients without CgA confounders were evaluated separately. The characteristics of both groups are presented in Table 1.

The treatment concept followed the national consensus recommendation for the use of PSMA RLT (18), with treatment cycles conducted every 8 wk. According to the consensus guidelines (18), PSMA treatment was reevaluated after 2 cycles. If patients were referred to our department and the uptake in the main tumor sites was too weak (uptake in most metastases at or below liver level), treatment was discontinued even after 1 cycle. In cases of an insufficient tumor response or a complete tumor response, other treatment concepts using different nuclides were initiated or therapy was stopped, respectively. Baseline blood work was checked before each cycle of PSMA RLT, and observational laboratory reports and results in between the treatment cycles were used for response assessment. As a clinical standard, LDH, PSA, and CgA were determined.

Lab Tests

Lab analysis for LDH was performed in an ADVIA Chemistry XPT (Siemens) using an enzyme-based method by catalysis of lactate to pyruvate. Measurement level was based on changes in wavelength at 340 nm. The reference blood level was less than 342 U/L. PSA was measured using a Zentaur XPT (Siemens) system with a chemiluminescent immunoassay (sandwich immunoassay). The reference blood

TABLE 1
Patient Characteristics

Characteristic	Total	Subgroup
Number of patients	100	65
Number of treatment cycles	211	129
Age at initial diagnosis (y)	62.5 ± 7.8	62.4 ± 6.7
Age at first cycle of PSMA RLT	69.8 ± 8.1	69.5 ± 6.7
Gleason score	8 (7–9)	8 (7–9)
Previous treatments (%)		
Radical prostatectomy	47	51
Radiation therapy to the prostate	56	58
Antihormonal treatment	100	100
Abiraterone	58	54
Enzalutamide	60	57
[223]Ra	6	6
Previous chemotherapy	40	34
Baseline PSA at RLT	59.11 (12.94–194.64)	28.35 (8.99–171.28)
Baseline CgA at RLT	118.6 (79.8–257.7)	91.3 (69.1–131.1)
Baseline LDH at RLT	248 (207–331)	239 (206–303)
Metastasis (%)		
Osseous	89	88
Bone marrow	11	6
Lymph nodes	71	69
Hepatic	15	12
Pulmonary	13	12
Brain	1	0
Other	10	11

Gleason score, PSA, LDH, and CgA are median followed by interquartile range in parentheses. Age is mean ± SD.

TABLE 2
Numbers of Patients with Respective Characteristics

Patient group	Visually graded tracer uptake in metastases			Clinical outcome			
	Faint	Heterogeneous	Intense	PR	SD	MR	PD
All 100	19	31	50	30	19	15	36
The 65 without CgA confounders	11	23	31	20	13	9	23

Faint = tracer uptake at or below liver level at baseline scintigraphy; heterogeneous = uptake between liver and salivary gland level at baseline scintigraphy; intense = uptake above salivary gland level at baseline scintigraphy; PR = partial remission (PSA < 50% of baseline level, tumor uptake < baseline level); SD = stable disease (change in PSA within −50% to +30% of baseline level, stable semiquantitative uptake and no new lesions in posttherapeutic imaging); MR = mixed response (change in PSA within −50% to +30% of baseline level, heterogeneous semiquantitative uptake in known lesions. No new lesions in posttherapeutic scintigraphy); PD = progression of disease (PSA > 30% of baseline level, occurrence of new lesions or increase in all known lesions).

level was less than 4 μg/L. Serum CgA was measured in a Kryptor Compact Plus (Thermo Fisher Scientific) using an immunofluorescence assay by means of trace technology for a cryptate-antibody-donator complex for immunocomplex measurement. The reference level was less than 84.7 ng/mL.

Biochemical response was defined as a PSA drop of more than 50%, biochemically stable disease was defined as a PSA of between −50% and +30%, and progression of disease was defined as a PSA increase of more than 30% in comparison to baseline.

PSMA Imaging

Posttherapeutic scintigraphy 20–24 h after injection (planar anterior and posterior whole-body scans in a dual-head γ-camera [Hawkeye Millennium; GE Healthcare] with medium-energy parallel-hole collimator, a scan speed of 15 cm/min, and the 208 keV ± 10% [187–228 keV] photo peak window) was evaluated at the first cycle. Two visually evaluable reference levels in grayscale were set (1: background uptake of the liver; 2: uptake of the salivary glands). If patients had a mainly tumor-related PSMA-617 uptake at or below liver level in the predominant tumor lesions, no further PSMA treatments were provided. At every cycle we performed a clinical examination, lab tests, and the posttherapeutic scintigraphy (20–24 h after injection). PSMA imaging was ^{99m}Tc-PSMA SPECT/CT in 15 patients, ^{68}Ga-PSMA11 PET/CT in 75, ^{18}F-PSMA1007 PET/CT in 8, and ^{18}F-DCFPYL in 2; restaging was performed with the modality already available at baseline.

Image Interpretation

On the basis of visual interpretation of baseline imaging, tracer uptake was categorized as intense, heterogeneous, or faint. Semiquantitative

tailoring into the 3 groups was performed by comparison of the average tumor uptake on baseline (at the first cycle) posttherapeutic scintigraphy to liver background and salivary gland background. Intense uptake was defined as uptake semiquantitatively above the salivary gland level on posttherapeutic scintigraphy. Heterogeneous uptake was defined as uptake above the liver grayscale level but below the salivary gland grayscale level. Faint uptake was defined as uptake at or below the liver grayscale level.

For statistical testing, only the categories partial remission and progression of disease were used. Partial remission was defined by a reduction of previously known PSMA-positive lesions and no new lesions. Progression was defined as the occurrence of new lesions or an increase in all known lesions.

For visual interpretation, we additionally introduced an arbitrary category named mixed response that was used for patients without new lesions, PSA of between −50% and +30%, but simultaneously presenting with increasing and decreasing old lesions.

Statistical Analysis

The results were initially assessed using Excel (version 2007; Microsoft Corp.). The main statistical analysis was then performed using function "glm" in R (version 3.4.0; R Foundation for Statistical Computing). The statistical significance level was set at a *P* value of less than 0.05.

Both a univariable and a multivariable logistic regression analysis were once performed on the dataset of 100 patients (with a total of 211 treatment cycles) and once on the subgroup of 65 patients without CgA confounders, investigating the effect of 3 independent variables (PSA before PSMA RLT, CgA before PSMA RLT, and LDH before

TABLE 3
Lab Evaluation Regarding the Clinical Outcome "Partial Remission" (*n* = 100), Evaluated by Univariable and Multivariable Logistic Regression Analysis

Parameter	Univariable model			Multivariable model		
	OR	95% CI	*P*	OR	95% CI	*P*
log10 PSA before PSMA RLT	0.461	0.265; 0.802	0.0061	0.505	0.227;1.123	0.0938
log2 CgA before PSMA RLT	0.780	0.549; 1.108	0.1657	0.955	0.594; 1.537	0.8501
log2 LDH before PSMA RLT	0.117	0.031; 0.441	0.0015	0.094	0.017; 0.518	0.0066
Heterogeneous tracer uptake (mainly below salivary glands and above liver uptake)	2.667	0.275; 25.838	0.3973	8.172	0.619; 107.879	0.1106
Intense tracer uptake (above salivary glands)	18.000	2.230; 145.319	0.0067	60.265	5.038;720.922	0.0012

TABLE 4
Lab Evaluation Regarding the Clinical Outcome "Progression of Disease" (n = 100)

Parameter	Univariable model			Multivariable model		
	OR	95% CI	P	OR	95% CI	P
log10 PSA before PSMA RLT	1.765	1.043; 2.985	0.0342	1.297	0.674; 2.497	0.4360
log2 CgA before PSMA RLT	1.597	1.144; 2.229	0.0060	1.416	0.949; 2.114	0.0883
log2 LDH before PSMA RLT	3.239	1.755; 5.979	0.0002	2.717	1.391; 5.304	0.0034
Heterogeneous tracer uptake (mainly below salivary glands and above liver uptake)	0.525	0.165; 1.670	0.2753	0.390	0.095;1.594	0.1899
Intense tracer uptake (above salivary glands)	0.230	0.075; 0.703	0.0099	0.165	0.044; 0.624	0.0079

Data were evaluated by univariable and multivariable logistic regression analysis.

PSMA RLT) as well as tracer uptake on the dependent variables partial remission and progression of disease. Tracer uptake was included in the form of 2 dummy variables, defined as heterogeneous uptake (yes vs. no) and intense versus faint uptake as the standard. To correct for skewed distributions, the quantitative variables were evaluated on a logarithmic scale (log 10 for PSA and log 2 for LDH and CgA). Different log transformations were used because of the different reference levels of the evaluated lab parameters and the probability of whether a 2-fold or a 10-fold increase represents a clinically meaningful difference. Results were expressed as odds ratios (ORs), with corresponding 95% confidence intervals (CIs) and P values. Additional univariable logistic regression analyses were performed in the same way to predict the presence of metastases at different locations depending on level of CgA only.

RESULTS

One hundred patients and a subgroup of 65 patients with, in total, 211 cycles of PSMA RLT were evaluated in a multivariable analysis (Table 1). Initial LDH, CgA, and PSA before RLT were selected for lab evaluation regarding the clinical outcome (either partial remission [yes vs. no] or progressive disease [yes vs. no]). Overall outcome data are presented in Table 2. Lab evaluation for univariable and multivariable analyses is presented in Tables 3–5.

Of the 100 evaluated patients, 35 had partial remission, 16 stable disease, 15 mixed response, and 36 progression of disease (Table 2).

LDH values before PSMA RLT were significant for outcome prediction. Using the univariable model, LDH before PSMA RLT showed an OR of 0.117 (95% CI, 0.031–0.441; P = 0.0015) regarding the clinical outcome. Using the multivariable model, LDH also indicated a reduced risk, with an OR of 0.094 (95% CI, 0.017–0.518; P = 0.006) for the complete group (n = 100). Elevated LDH had an increased risk for progression in the univariable model, with an OR of 3.239 (95% CI, 1.755–5.979; P = 0.0002), and in the multivariable model, with an OR of 2.717 (95% CI, 1.391–5.304; P = 0.003). Baseline LDH values in comparison to outcome (PSA at restaging) are shown in Figure 1.

About the prognosis for partial remission, CgA showed no significance for outcome prediction (P = 0.1657 for the univariable model and P = 0.8501 for the multivariable model). Regarding progressive disease, CgA showed elevated risk in the univariable model, with an OR of 3.385 (95% CI, 1.597–7.175; P = 0.0015), and in the multivariable model, with an OR of 3.089 (95% CI, 1.302–7.332; P = 0.011), in the subgroup without confounders (n = 65). For the group of all patients, the effect was weaker and barely not significant using the multivariable analysis (P = 0.08) but remained significant for the univariable model, with an OR of 1.597 (95% CI, 1.144–2.229; P = 0.006).

Elevated CgA before RLT had an increased risk for organ metastases in the liver, with an OR of 1.861 (95% CI, 1.048–3.305; P = 0.0341), for all patients. In the subgroup, results stayed robust

TABLE 5
Lab Evaluation Regarding the Clinical Outcome "Progression of Disease" Without Confounders for CgA Measurement (Patients Without Evaluable Confounders As Pantoprazole or Gastritis or Renal Failure) (n = 65)

Parameter	Univariable model			Multivariable model		
	OR	95% CI	P	OR	95% CI	P
log10 PSA before PSMA RLT	2.706	1.326; 5.523	0.0062	2.099	0.821; 5.365	0.1215
log2 CgA before PSMA RLT	3.385	1.597; 7.175	0.0015	3.089	1.302; 7.332	0.0105
log2 LDH before PSMA RLT	3.275	1.386; 7.738	0.0069	1.605	0.600; 4.290	0.3456
Heterogeneous tracer uptake (mainly below salivary glands and above liver uptake)	1.346	0.307; 5.911	0.6937	1.185	0.138; 10.207	0.8774
Intense tracer uptake (above salivary glands)	0.716	0.167; 3.061	0.6521	0.432	0.063; 2.961	0.3931

Data were evaluated by univariable and multivariable logistic regression analysis.

FIGURE 1. LDH at first cycle of PSMA RLT in comparison to percentage change in PSA at restaging. Dashed line depicts upper limit of LDH (342 U/L).

for organ metastases in the liver, with an OR of 1.527 (95% CI, 1.034–2.255; $P = 0.0333$). For all other organ or soft-tissue metastases, there was no significantly elevated risk associated with CgA (Tables 6 and 7). Baseline CgA values in comparison to outcome (PSA at restaging) for the group with progression are shown in Figure 2.

PSA level before RLT was not significant using the multivariable analysis for prediction of either partial remission ($P = 0.0938$) or progression of disease ($P = 0.436$). No significant odds can be provided, therefore (Tables 3–5). For the univariable model, significant odds can be provided for partial remission, with an OR of 0.461 (95% CI, 0.265–0.802; $P = 0.0061$), and for progression of disease, with an OR of 1.765 (95% CI, 1.043–2.985; $P = 0.0342$). For imaging evaluation, an intense tumor uptake (above salivary gland level) was significant for prediction of partial remission. The ORs for intense uptake and partial remission were 18.0 (95% CI, 2.230–145.3119; $P = 0.0067$) for the univariable model and 60.265 (95% CI, 5.038–720.922; $P = 0.001$) for the multivariable model. For progression of disease, intense tumor uptake had a protective OR of 0.230 (95% CI, 0.075–0.703; $P = 0.0099$) for the univariable model and 0.165 (95% CI, 0.044–0.624; $P = 0.0079$) for the multivariable model (Tables 3–5). However, not all patients with intense tumor uptake ($n = 50$) had a partial remission ($n = 30$) (Table 2). A waterfall graph of all 100 patients (Fig. 3) compares the PSA response to baseline and to the results of posttherapeutic scintigraphy. Thirty-one patients had a PSA drop of 50% or more in comparison to baseline. Fifty-one patients had any PSA response. Two patients had no PSA response and remained at a stable PSA level although imaging showed a decreased tracer uptake. Thirty-one patients had PSA progression, 26 of whom had PSA progression of more than 30%. Twenty-six of 51 patients had a PSA response and a response on posttherapeutic scintigraphy. Twenty-one of 51 patients had a PSA response and stable disease or a mixed response on imaging. Four of 51 patients had progression on imaging although a PSA response was detectable. Thirteen of 31 patients had stable disease or a mixed response with a PSA rise at restaging. Seventeen of 31 patients had visual and biochemical progression. One of 31 patients had a visual response on posttherapeutic scintigraphy although he

had a PSA rise of more than 100%; in this case, we assume a PSMA-negative tumor phenotype.

DISCUSSION

PSMA RLT is an emerging approach to treat advanced-stage prostate cancer patients. The aim of this study was to evaluate whether CgA has a prognostic value for response prediction and how this biomarker compares with the established tumor markers PSA and LDH.

PSMA PET or SPECT is routinely performed in advance of PSMA RLT to select only patients positive for the target receptor. However, only a moderate correlation ($r = 0.61$) between PSMA PET and tumor uptake during therapy was found (19). This result might be explained by the different structures of the imaging tracers that have been optimized for rapid tumor targeting but are only surrogates for PSMA-617, which has been optimized for therapy. In addition, no PSMA imaging agent has yet been approved, but several compounds are under investigation. To relay on a common standard, we semiquantitatively assessed (tumor-to-salivary gland, tumor-to-liver) PSMA uptake with the emission scan of the first treatment cycle. Homogeneously high uptake was a prerequisite to achieve partial remission, and the high OR

TABLE 6
OR and 95% CI for Presence of Metastases Depending on Level of CgA: Subgroup of Patients Without Evaluable Confounders Such as Pantoprazole or Gastritis or Renal Failure ($n = 65$)

Metastasis	OR	Lower limit	Upper limit	P
Bone	1.178	0.576	2.407	0.6541
Bone marrow	1.200	0.578	2.491	0.6249
Lymph nodes	1.249	0.751	2.076	0.3916
Liver	1.861	1.048	3.305	0.0341
Lung	1.089	0.603	1.966	0.7785
Brain	—			
Others	1.245	0.703	2.205	0.4525

Data were evaluated by univariable logistic regression analysis.

TABLE 7
OR and 95% CI for Presence of Metastases Depending on Level of CgA: All Patients ($n = 100$)

Metastasis	OR	Lower limit	Upper limit	P
Bone	1.259	0.744	2.130	0.3901
Bone marrow	1.340	0.872	2.059	0.1822
Lymph nodes	1.142	0.815	1.600	0.4415
Liver	1.527	1.034	2.255	0.0333
Lung	1.273	0.848	1.911	0.2441
Brain	0.782	0.145	4.233	0.7758
Others	1.167	0.736	1.848	0.5116

Data were evaluated by univariable logistic regression analysis.

FIGURE 2. CgA at first cycle of PSMA RLT in comparison to percentage change in PSA at restaging for group with progression of disease. Dashed line depicts upper limit of CgA (84.7 ng/mL). Blue diamonds are patients without potential confounders. Orange diamonds are patients with potential confounders.

observed demonstrates the appropriateness of this approach. These findings are well in line with expectations and previously published studies (*19,20*).

We observed that baseline PSA, which is considered to reflect baseline tumor volume, had no significance for response prediction. This result is in line with previously published data, as not the baseline PSA but the PSA response seems to be more meaningful (*21*).

The strongest value for response prediction was baseline LDH, a cytosolic enzyme that is released to serum in correlation with cell turnover and thus reflects an unspecific surrogate for the aggressiveness of tumor growth. This result is well in line with former studies, as LDH was previously described to be a relevant marker for response prediction (*21,22*) and associated with progression-free survival (*21*).

For the patients without CgA confounders, an elevated baseline CgA was related to an increased risk for progression (OR, 3.09; $P < 0.05$). However, it was no more significant ($P = 0.08$) if the patients with confounders were also included; this inclusion rendered 35 of 100 patients unevaluable. Nevertheless, the OR reflects only an average risk; individual patients with elevated baseline CgA could also achieve partial remission.

In both evaluated cohorts (with and without CgA confounders), a statistically significant association between CgA and the presence of liver metastases was found. There were no relationships between CgA and metastases in lung, brain, or other organs.

Although the role of neuroendocrine cells in prostate cancer is not completely understood, paracrine effects and stimuli on growth regulation are well known (*23*), and overexpressing the antiapoptotic protein survivin leads to resistance to programmed cell death (*5,24*). With an increase of neuroendocrine cells in late-stage metastasized castration-resistant prostate cancer (initially more scattered neuroendocrine cells or small nests among the predominant epithelial cells in early stages) (*25–27*), this pattern might become more relevant in liver metastases, as poor differentiation and neuroendocrine differentiation are more present (*28,29*). Therefore, we assume a higher incidence of PSMA-negative tumor phenotype at these hepatic tumor sites. For clinical practice, an elevated CgA and nonresponse to PSMA RLT might indicate a PSMA-negative tumor, especially in the liver. However, other variables also need to be taken in account, such as mutations in tumor suppression genes, because patients without liver metastasis and with normal CgA also had a nonresponse to PSMA treatment (*30*). This finding implies that in patients with a high baseline CgA, special focus should be given to liver imaging.

The main limitation of the present evaluation is its single-center, retrospective design. Furthermore, CgA elevation is described not only for neuroendocrine tumors but also for chronic atrophic gastritis, use of proton pump inhibitors, renal failure, and chronic heart failure (*14–17*) and might be present without pathologic cause. Especially, proton pump inhibitors are widely used in patients after treatment with second-generation antihormonal therapies (abiraterone acetate and enzalutamide), and concomitant treatment with steroids (prednisone) might cause a CgA elevation without any existing pathology. Also, it should be noted that for the absolute values of tumor markers, the reference range is defined as the mean ± 2 SDs, and 2.5% of the healthy population will physiologically have values above the upper limit (*31*). Because PSMA RLT is a last-line therapy and patients usually received second-generation antihormonal treatments with concomitant antacid, our results for CgA should be cautiously transferred into clinical practice and a validation of our results in a prospective design should be performed.

CONCLUSION

Although CgA demonstrated some potential as a negative prognostic biomarker, it was found to be inferior to LDH, and its clinical value is remarkably hampered by numerous confounders that can nonspecifically increase its serum level in more than one third of patients. In contrast to other markers, elevated CgA is associated with an increased risk for liver metastasis and might be used to guide liver-specific imaging.

DISCLOSURE

FIGURE 3. Waterfall graph of PSA response compared with color-coded response in imaging.

Legend:
- Patients with partial remission in post therapeutic (p.t.) scintigraphy
- Patients with stable disease or mixed response in p.t. scintigraphy
- Patients with progression in p.t. scintigraphy
- Patients ($n = 16$) lost to imaging follow up and progression was assumed

for PSMA-617. No other potential conflict of interest relevant to this article was reported.

KEY POINTS

QUESTION: Is response in prostate cancer to PSMA RLT predictable by lab measurement before the first cycle?

PERTINENT FINDINGS: In this retrospective single-center evaluation, 100 patients under PSMA RLT were evaluated by comparing their baseline lab values before RLT with their clinical outcome. The most beneficial constellation of lab parameters was a high tumor uptake of tracer-associated activity in combination with a low LDH and a low CgA before PSMA RLT.

IMPLICATIONS FOR PATIENT CARE: If LDH or CgA was elevated before PSMA RLT, patients had an elevated risk for non-response and progression of disease under therapy and an elevated risk for liver metastases.

REFERENCES

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol.* 2009;6:76–85.
2. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med.* 2012;367:1187–1197.
3. Kratochwil C, Haberkorn U, Giesel FL. Radionuclide therapy of metastatic prostate cancer. *Semin Nucl Med.* 2019;49:313–325.
4. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. *Cancer Discov.* 2011;1:466–468.
5. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. *Front Oncol.* 2015;5:90.
6. Burgio SL, Conteduca V, Menna C, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. *Endocr Relat Cancer.* 2014;21: 487–493.
7. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. *Crit Rev Oncol Hematol.* 2014;92:11–24.
8. Hong P, Guo RQ, Song G, et al. Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis. *Asian J Androl.* 2018;20: 561–566.
9. Ischia R, Hobisch A, Bauer R, et al. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. *J Urol.* 2000;163:1161–1164.
10. Hirano D, Minei S, Sugimoto S, et al. Implications of circulating chromogranin A in prostate cancer. *Scand J Urol Nephrol.* 2007;41:297–301.
11. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. *J Urol.* 2002;167:512–515.
12. Braga F, Ferraro S, Mozzi R, Dolci A, Panteghini M. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. *Clin Biochem.* 2013;46:148–151.
13. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. *Hum Pathol.* 2007;38:696–701.
14. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. *Scand J Gastroenterol.* 1997;32:198–202.
15. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. *Gut.* 1996;39:649–653.
16. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. *Kidney Int.* 1990;37:955–964.
17. Marotta V, Nuzzo V, Ferrara T, et al. Limitations of chromogranin A in clinical practice. *Biomarkers.* 2012;17:186–191.
18. Fendler WP, Kratochwil C, Ahmadzadehfar H, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer [in German]. *Nuklearmedizin.* 2016;55:123–128.
19. Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of ^{177}Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. *J Nucl Med.* 2019;60:517–523.
20. Scarpa L, Buxbaum S, Kendler D, et al. The ^{68}Ga/^{177}Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. *Eur J Nucl Med Mol Imaging.* 2017;44:788–800.
21. Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with ^{177}Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. *Eur Urol.* 2019;75:920–926.
22. Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with ^{177}Lu-PSMA-617. *J Nucl Med.* 2017;58:312–319.
23. Gunia S, Albrecht K, Koch S, et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. *World J Urol.* 2008;26: 243–250.
24. Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. *Urology.* 2005;66:386–391.
25. Bostwick DG, Qian J, Pacelli A, et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. *J Urol.* 2002;168:1204–1211.
26. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. *Urology.* 1998;51:585–589.
27. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. *Am J Transl Res.* 2009;1:148–162.
28. Pouessel D, Gallet B, Bibeau F, et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. *BJU Int.* 2007;99:807–811.
29. Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. *J Clin Oncol.* 2018;36:2492–2503.
30. Apostolidis L, Nientiedt C, Winkler EC, et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. *Oncotarget.* 2019;10:17–29.
31. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. *Scand J Gastroenterol.* 2004;39:969–973.